Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus TPF versus TPF alone as neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma
ChiCTR2100045556Phase 4Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of toripalimab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Sichuan Cancer Hospital. Primary endpoints: Major pathological response and Safety and tolerability. Started Jan 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2100045556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045556.